Document Detail


Cetuximab-based therapy is effective in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
MedLine Citation:
PMID:  21424607     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Randomized controlled trails (RCTs) where cetuximab added to first-line platinum-based chemotherapy for patients with advanced/metastatic non-small-cell lung cancer (NSCLC) have yielded conflicting results. This meta-analysis intended to evaluate the efficacy and safety of cetuximab-based therapy (CBT) in that setting. We analyzed four eligible RCTs that included 1,003 and 1,015 patients randomized to CBT and control intervention, respectively. As compared with the noncetuximab group, CBT demonstrated an 9% reduction in the risk of disease progression [hazard ratio (HR) = 0.91; (CI = 0.83-1.00); p = 0.06], a 13% reduction in the risk of death [HR = 0.87; (CI = 0.78-0.96); p = 0.005], and an approximately 50% increase in objective response rate [odds ratio (OR) = 1.48; (CI = 1.22-1.80); p < 0.0001]. CBT-related adverse events were similar across comparisons except for toxicities known to be associated with anti-EGFR therapy. CBT produced significant clinical benefit with acceptable toxicity as a first-line strategy in patients with advanced/metastatic NSCLC. Further research is needed to identify markers predictive of cetuximab benefit in that disease.
Authors:
Ezzeldin M Ibrahim; Khaled M Abouelkhair; Osama A Al-Masri; Najeeb C Chaudry; Ghieth A Kazkaz
Related Documents :
18345307 - Interferon receptor alpha/beta is associated with improved survival after adjuvant ther...
21931127 - Strategy for second kidney biopsy in patients with lupus nephritis.
21482587 - Postoperative radiotherapy for resected pathological stage iiia-n2 non-small cell lung ...
8922197 - Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinbl...
18592787 - Interval debulking in epithelial ovarian carcinomas: the past, present and the future.
6871827 - A phase ii study on the postsurgical management of stage ii malignant melanoma with a n...
Publication Detail:
Type:  Journal Article; Meta-Analysis     Date:  2011-03-20
Journal Detail:
Title:  Lung     Volume:  189     ISSN:  1432-1750     ISO Abbreviation:  Lung     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-05-31     Completed Date:  2011-09-26     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  7701875     Medline TA:  Lung     Country:  United States    
Other Details:
Languages:  eng     Pagination:  193-8     Citation Subset:  IM    
Affiliation:
Oncology Center of Excellence, International Medical Center, Kingdom of Saudi Arabia. ezzibrahim@imc.med.sa
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antibodies, Monoclonal / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*,  genetics,  mortality,  secondary
Disease-Free Survival
Evidence-Based Medicine
Female
Humans
Lung Neoplasms / drug therapy*,  genetics,  mortality,  pathology
Male
Middle Aged
Odds Ratio
Randomized Controlled Trials as Topic*
Receptor, Epidermal Growth Factor / antagonists & inhibitors,  genetics
Risk Assessment
Risk Factors
Survival Analysis
Survival Rate
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; EC 2.7.10.1/EGFR protein, human; EC 2.7.10.1/Receptor, Epidermal Growth Factor; PQX0D8J21J/cetuximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cutaneous Hyalohyphomycosis Caused by Paecilomyces lilacinus Successfully Treated by Oral Voriconazo...
Next Document:  Mitotic lymphoma cells are characterized by high expression of phosphorylated ribosomal S6 protein.